Evidence map›Paper›PMID 42249084›Full record

ArticleAnnals of hematology2026

What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation.

Stefan W Krause, Wolfgang Bethge, Gesine Bug, Ahmet Elmaagacli, Edgar Jost, Stefan A Klein, Guido Kobbe, Sabrina Kraus, William H Krüger, Thomas Luft and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Stefan W KrauseDepartment of Medicine 5, Uniklinikum Erlangen, Erlangen, Germany. stefan.walter.krause@fau.de.ORCID http://orcid.org/0000-0002-5259-4651
Wolfgang BethgeDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Gesine BugDepartment of Medicine 2, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
Ahmet ElmaagacliAbteilung für Hämatologie/Onkologie und Stammzelltransplantation, Asklepios Klinik St.Georg, Hamburg, Germany.
Edgar JostDepartment of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Stefan A KleinDepartment of Haematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Guido KobbeDepartment of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Sabrina KrausDepartment of Internal Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany.
William H KrügerKlinik für Innere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany.
Thomas LuftDepartment of Hematology and Oncology, University of Heidelberg, Heidelberg, Germany.
Lutz P MüllerUniversitätsklinik für Innere Medizin IV, Universitätsklinikum Halle, Halle, Germany.
Kerstin Schäfer-EckartDepartment of Internal Medicine 5, Klinikum Nuernberg, Paracelsus Medizinische Privatuniversität, Nürnberg, Germany.
Johannes ScheteligMedizinische Klinik und Poliklinik I, Universitätsklinikum TU Dresden, Dresden, Germany.
Normann SteinerDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
Matthias StelljesDepartment of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
Johanna TischerDepartment of Internal Medicine III, LMU, University Hospital Munich, Campus Grosshadern, Munich, Germany.
Julia WinklerDepartment of Medicine 5, Uniklinikum Erlangen, Erlangen, Germany.
Daniel WolffDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Friederike WortmannKlinik für Hämatologie und Onkologie, UKSH Campus Lübeck, Lübeck, Germany.
Christoph RölligMedizinische Klinik und Poliklinik I, Universitätsklinikum TU Dresden, Dresden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoetic stem cell transplantation (allo SCT) is a treatment option with a unique chance of cure for patients with high-risk AML or MDS. However, the optimal path for an individual patient on its way to allo SCT is far from clear and subject of ongoing debates. Upfront transplantation "as soon as possible" competes with strategies to achieve deep remission or at least stabilization of the disease. In this context, we performed a survey among German transplant centers to assess their preferred strategies for patients before SCT in five typical scenarios of AML and MDS. We obtained replies from 22 centers, revealing a heterogenous use of possible strategies. Upfront transplantation was a preferred option (68%) in intermediate risk MDS, chemotherapy was preferred (64%) as bridging for AML in remission, whereas hypomethylating agents (HMA) and induction chemotherapy for relapsed AML were highly controversial. Further prospective evaluation of different options is desirable.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesBridge TherapyFemaleGermanyHumansInduction ChemotherapyMaleSurveys and QuestionnairesTransplantation, HomologousBridgingHematopoietic stem cell transplantationInduction chemotherapyStandard of care

Identifiers

PMID42249084
PMCPMC13241428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.